The purpose of the study is to find out which doses of AEF0217 given over 24 weeks can help improve daily living skills and behaviors compared to placebo, and to see how these effects develop over time and whether they differ based on age, level of disability, certain genes, and blood levels of specific substances at the start of the study. The study will also look at whether the treatment can improve thinking skills, language abilities, quality of life, and sleep, and will check if the treatment is safe and well tolerated.

The study will last for 32 weeks in total. During the first 24 weeks, participants will take either AEF0217 or placebo every day. Throughout the study, participants will have regular visits where different tests and questionnaires will be done to measure changes in adaptive behaviors, which are the everyday skills needed for living independently, as well as thinking abilities, language skills, quality of life, mood, anxiety, and sleep quality. Safety will be monitored throughout the study by checking vital signs like blood pressure and heart rate, doing blood and urine tests, and performing heart monitoring tests. After the 24 weeks of treatment, there will be an additional 8-week period to continue monitoring participants.

The purpose of the study is to gather information on how well [18F]PI-2620 works in identifying tau protein build-up in the brain, which is linked to Alzheimer’s disease in people with Down syndrome. The study will also look at the safety of this imaging agent in both healthy individuals and those with Down syndrome. Participants will receive the injection of [18F]PI-2620 and then undergo a PET scan to see how the agent highlights areas of the brain affected by tau protein.

Throughout the study, participants will be monitored for any side effects for 24 hours after receiving the injection. The study aims to provide valuable insights into the use of [18F]PI-2620 for better understanding and potentially diagnosing Alzheimer’s disease in individuals with Down syndrome over time.

The study will compare two groups of participants over a period of 96 weeks (about 2 years). One group will receive levetiracetam tablets (either 250 mg or 500 mg), while the other group will receive placebo tablets. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition.

During the study, doctors will track several aspects of participants’ health, including brain activity through electroencephalography (a test that records electrical signals from the brain), brain structure using MRI (a type of detailed brain scan), and various blood tests. They will particularly focus on watching for seizures and checking how well the medication is tolerated by participants.

The purpose of the study is to explore whether Bumetanide can improve cognitive functions in children and adolescents with Down syndrome. Participants in the study will take the medication or placebo for a period of three months. During this time, researchers will assess changes in cognitive abilities and other related aspects, such as memory and behavior, to determine the effectiveness of the treatment.

The study aims to provide insights into whether Bumetanide can be a beneficial treatment for improving cognitive functions in young individuals with Down syndrome. The trial is designed to be safe, as Bumetanide has been used in humans before with minimal side effects. The results could potentially lead to new treatment options for enhancing the quality of life for those affected by this condition.

The purpose of the study is to understand how sleep and body temperature might influence the development of Alzheimer’s disease in people with Down syndrome. Participants will receive an injection of the imaging agent [18F]PI-2620 through a slow injection into a vein. This will allow researchers to take detailed images of the brain using a technique called magnetic resonance imaging (MRI). These images will help in assessing changes in the brain over time.

The study will follow participants over a period to observe any changes in their brain structure and function. The information gathered from this study could provide valuable insights into how sleep and body temperature affect Alzheimer’s disease progression in individuals with Down syndrome. Participants will be monitored for any changes in their condition, and the results will contribute to a better understanding of these complex interactions.

The purpose of the study is to evaluate the effectiveness of this treatment in achieving a specific outcome known as event-free survival, which refers to the time from diagnosis until a significant event occurs, such as a relapse or a new cancer. The study will involve children with Down Syndrome who have been diagnosed with Myeloid Leukemia. Participants will receive the treatment over a period of time, and their health will be monitored to see how well the treatment works and to observe any side effects.

Throughout the study, researchers will collect information on various aspects of the participants’ health, including overall survival, which is the time from diagnosis to death from any cause, and disease-free survival, which is the time after treatment during which the patient remains free of disease. The study will also look at the early response rate to the treatment and any treatment-related side effects. The goal is to gather data that will help improve treatment options for children with this type of leukemia.